Unlock instant, AI-driven research and patent intelligence for your innovation.

Polycrystalline type forms of 2-aminopyrimidine compound

A technology of compounds and crystal forms, applied in the field of medicinal chemistry, can solve the problems such as the clinical pressure of drug resistance and the side effects of wild-type cytotoxicity.

Active Publication Date: 2017-12-01
JIANGSU AOSAIKANG PHARMA CO LTD +2
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the current EGFR-TKI still cannot solve the clinical pressure caused by drug resistance, and most of the existing drugs are EGFR reversible or irreversible inhibitors based on quinazoline or quinoline amines. Toxic side effects caused by poor selectivity of wild-type cells are also inevitable

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polycrystalline type forms of 2-aminopyrimidine compound
  • Polycrystalline type forms of 2-aminopyrimidine compound
  • Polycrystalline type forms of 2-aminopyrimidine compound

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0167] The preparation of the compound of formula (I) is as follows:

[0168]

[0169] 2,4,5-Trichloropyrimidine (9g, 49mmol), 2-naphthylamine (7.38g, 51.6mmol), sodium carbonate (10.41g, 98.1mmol) were dissolved in absolute ethanol (150mL), and stirred overnight at room temperature. Ice water (450 mL) was added with stirring, and a large amount of solid precipitated out. Filter under reduced pressure and dry in vacuo to obtain brown solid compound Int-01 (12.57 g, yield 88%).

[0170]Add 2,5-dichloro-N-(naphthalene-2-yl)pyrimidin-4-amine (Int-01, 10.00g, 34.4mmol), 2-methoxy-4-fluoro-5- Add anhydrous isopropanol (115 mL) to nitroaniline (6.41 g, 34.4 mmol), p-toluenesulfonic acid monohydrate (7.86 g, 41.3 mmol), and reflux overnight at 83°C. After the reaction, the reaction solution was cooled to room temperature, filtered, and a mixture of ammonia (5.8 mL) and water (50 mL) was added to the solid, stirred for 2 to 3 hours, filtered, washed with water (25 mL), and dried ...

Embodiment 1

[0230] Embodiment 1: the preparation of crystal form I

[0231] Method 1: Dissolve 1 g of the crude compound of formula (I) in 30 ml of ethyl acetate at 60°C, add 30 ml of methyl tert-butyl ether, cool to room temperature, stir overnight, filter, and dry to obtain Form I.

[0232] Method 2: Dissolve 1 g of the crude compound of formula (I) in 30 ml of acetone, stir for 2 hours, place in a refrigerator at 4°C overnight, filter, and dry to obtain Form I.

[0233] The XRD pattern of obtained crystal form I is shown in figure 1 , the diffraction angle data are basically shown in Table 1 below. The TG spectrum of crystal form I is basically as figure 2 shown. The DSC spectrum of crystal form I is basically as image 3 shown.

[0234] It can be seen that the crystal form I is an anhydrous, diamond-shaped block crystal with a melting point of about 177.68°C, no crystal transformation behavior before melting, and begins to decompose at about 250°C. The DVS experiment shows that...

Embodiment 2

[0238] Embodiment 2: the preparation of crystal form II

[0239] Method 1: Take 1 g of the crude compound of formula (I) and dissolve it in a mixed solvent of methanol and water (20 ml, 1:1) at 50°C, cool down and stir for crystallization, filter, and dry to obtain crystals.

[0240]Method 2: Take 1 g of the crude compound of formula (I) and dissolve it in a mixed solvent of acetonitrile and water (30 ml, 2:1) at 50°C, cool down and stir for crystallization, filter, and dry to obtain crystals.

[0241] The XRD pattern of obtained crystal form I is shown in Figure 4 , the diffraction angle data are basically shown in Table 2 below. The TG spectrum of crystal form II is as follows Figure 5 shown. The DSC spectrum of crystal form II is as follows Figure 6 shown.

[0242] It can be seen that the crystal form II is a dihydrate, a columnar crystal. It begins to lose water and weight at about 80°C when it is heated, and loses two molecules of water at 150°C and turns into a c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
melting pointaaaaaaaaaa
Login to View More

Abstract

The invention provides polycrystalline type forms of a 2-aminopyrimidine compound. Specifically, the invention provides N-((5-((5-chloro-4-((naphthyl-2-yl)amino))pyrimidine-2-yl)-amino)-2-((N-methyl-N-dimethylamino ethyl)amino)-4-methoxyphenyl)acrylamide, polycrystalline type substances thereof, a preparation method and application.

Description

technical field [0001] The invention belongs to the field of medicinal chemistry, in particular, the invention relates to compound N-((5-((5-chloro-4-((naphthalene-2-yl) amino)) pyrimidin-2-yl) amino)-2 -((N-methyl-N-dimethylaminoethyl)amino)-4-methoxyphenyl)acrylamide and its polymorph, application and preparation method. Background technique [0002] Protein tyrosine kinases (PTKs) are a class of protein enzymes that can catalyze the phosphorylation of phenolic hydroxyl groups on tyrosine residues of various important proteins, thereby activating the function of functional proteins. Studies have shown that the activation of more than half of proto-oncogenes and oncogenes is related to protein tyrosine kinases. The research and development of anti-tumor drugs targeting tyrosine kinases has become an international hotspot, and it is also the focus of research investment by drug development institutions in various countries. [0003] Epidermal growth factor receptor (EGFR),...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D239/48A61K31/505A61P35/00
CPCC07B2200/13C07D239/48A61K31/505A61K31/506A61K31/5377C07D239/47C07D401/02C07D403/12
Inventor 梅雪锋丁克丁健谢华陈成斌赵俊宋婷婷宗在伟孙敏
Owner JIANGSU AOSAIKANG PHARMA CO LTD